TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05622864

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HRS-9821
Description: HRS-9821

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HRS-9821
Description: HRS-9821
Study: NCT05346120

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: allogeneic marrow stromal cells (MSCs)
Description: stem cell infusion

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: allogeneic marrow stromal cells (MSCs)
Description: stem cell infusion
Study: NCT05889728

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [68Ga]GA-NeoB
Description: Is a positron emission tomography (PET) imaging agent, intended as a selection tool for \[177Lu\]Lu-NeoB treatment in patients with tumors overexpressing gastrin releasing peptide receptor (GRPR).
Study: NCT04715243

Intervention type: DEVICE
Group type: OTHER
Intervention: Face-mask NIV
Description: NIV interface
Study: NCT06413576

Intervention type: DIAGNOSTIC_TEST
Intervention: homocysteine measurement
Description: measuring the serum level of homocysteine

Intervention type: DIAGNOSTIC_TEST
Intervention: homocysteine measurement
Description: measuring the serum level of homocysteine

Intervention type: DIAGNOSTIC_TEST
Intervention: homocysteine measurement
Description: measuring the serum level of homocysteine
Study: NCT05836441

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Exposure to white patches
Description: Exposure to white patches

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Exposure to edge of white patches and normal skin around white patches
Description: Exposure to edge of white patches and normal skin around white patches
Study: NCT04337177

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VAL-413
Description: a flavored preparation of orally administered irinotecan

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VAL-413
Description: a flavored preparation of orally administered irinotecan

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VAL-413
Description: a flavored preparation of orally administered irinotecan

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: alkylating oral chemotherapy agent used to treatment brain cancers

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: alkylating oral chemotherapy agent used to treatment brain cancers

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: alkylating oral chemotherapy agent used to treatment brain cancers
Study: NCT05222984

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Navitoclax
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Given PO
Study: NCT05351944

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dialectical behavioral therapy skills for the intervention experimental group A
Description: Our hypothesis is that impulsive aggression as evidenced by inflammatory biomarkers might improve by targeting executive dysfunctions with Dialectical Behavioural Therapy skills modules directed to the children and their parents in the form of response inhibition dysfunctions with Dialectical Behavioural Therapy mindfulness and distress tolerance skills modules, emotion regulation executive dysfunctions with Dialectical Behavioural Therapy emotion regulation skills module and socioenvironmental factors with interpersonal effectiveness and walking the middle path Dialectical behavioural therapy skills modules.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: psychoeducation or Atomoxetine or stimulants according to ADHD severity
Description: the control group (group B) will receive psychoeducation and medications targeting ADHD symptoms (Atomoxetine or stimulants according to FDA approved dose according to age and weight ) according to the international guidelines for management of ADHD according to symptom severity
Study: NCT05941793

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MBS-COV
Description: MBS-COV for inhalation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MBS-COV
Description: MBS-COV for inhalation

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo for inhalation
Study: NCT04890652

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Digital intervention
Description: All participants will receive a digital intervention designed to reduce stress and alcohol consumption over a 4-week period. The intervention will include two weekly sessions that integrate alcohol intervention with breathing-based stress management techniques.
Study: NCT04696380

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine
Description: Participants will sample high vs low nicotine.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine
Description: Participants will sample high vs low nicotine.
Study: NCT05924633

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Supplement containing a protein hydrolysate + beta glucan (Wellmune®)
Description: Supplement taken daily for 4 weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo supplement containing maltodextron
Description: Placebo supplement taken daily for 4 weeks.
Study: NCT05389293

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mosunetuzumab
Description: During Cycle 1, mosunetuzumab will be administered SC in a step-up dosing schedule at the dose of 5 mg on Day 1, 45 mg on Day 8, and 45 mg on Day 15). Beginning with Cycle 2, mosunetuzumab will be administered SC at the dose of 45 mg on Day 1. Each Cycle lasts 3 weeks. After the first 8 cycles (approximately 6 months) of therapy, subjects who achieved CR will discontinue therapy, those who attained a PR will receive up to 17 doses (approximately 12 months). Subjects who achieve stable disease (SD) or who experience progressive disease (PD) will be taken off study and subsequent management will be left at the discretion of the investigator.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mosunetuzumab
Description: During Cycle 1, mosunetuzumab will be administered SC in a step-up dosing schedule at the dose of 5 mg on Day 1, 45 mg on Day 8, and 45 mg on Day 15). Beginning with Cycle 2, mosunetuzumab will be administered SC at the dose of 45 mg on Day 1. Each Cycle lasts 3 weeks. After the first 8 cycles (approximately 6 months) of therapy, subjects who achieved CR will discontinue therapy, those who attained a PR will receive up to 17 doses (approximately 12 months). Subjects who achieve stable disease (SD) or who experience progressive disease (PD) will be taken off study and subsequent management will be left at the discretion of the investigator.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zanubrutinib
Description: In Cohort 2, zanubrutinib is concurrently administered continuously starting on Cycle 1, Day -7 and is given for 12 months in both patients with CR and those with PR
Study: NCT05840198

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Recovery & Care Canine-Assisted Therapy
Description: Active intervention. An 6-week session of structured, goal-oriented activities where youth focus on mastering dog obedience and dog training skills. Each session is 1 hour and 15 minutes in length and includes education, review of prior sessions, and specific skill-building activities. Skill-building activities progress in complexity during the course of the 6-week curriculum.

Intervention type: OTHER
Group type: OTHER
Intervention: Treatment as usual
Description: Youth in this condition receive treatment as usual from their health care providers
Study: NCT06479343

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Liquid Embolic System (Tonbridge)
Description: Endovascular treatment with Liquid Embolic System (Tonbridge).

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Onyx Liquid Embolic System (Medtronic)
Description: Endovascular treatment with Onyx Liquid Embolic System (Medtronic).
Study: NCT05363267

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: curcumin, high phenolic extra virgin olive oil (HP-EVOO)
Description: identical for all participants with the exception of the curcumin dose level~Dose 1: 1000 mg Curcumin daily dose with 1 capsule of 25 ml HP-EVOO volume at morning and night Dose 1: 2000 mg Curcumin daily dose with 2 capsules of 25 ml HP-EVOO volume at morning and night Dose 3: 4000 mg Curcumin daily dose with 4 capsules of 25 ml HP-EVOO volume at morning and night
Study: NCT05174247

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: FFRct analysis
Description: Software analysis of Cardiac CT to show extent of pericardial stenoses
Study: NCT03994874

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PolyCore (Polydextrin, L-Carnitine, D-xylitol)
Description: A single nightly exchange, with 2 liters PolyCore solution, lasting 12-14 hours. Patients should remain on their prescribed heart failure medications and the same dosing schedule for the duration of the study unless investigators determine medically necessary to change.
Study: NCT06174246

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Pain self-management program
Description: Agir pour moi (Acting for me) is a chronic pain self-management program designed to be followed independently online. The eight modules, normally spread over eight weeks and taking about 60 to 90 minutes per week to complete, focus on different strategies for managing pain on a daily basis.~The structured lessons include videos, audio capsules, activities, and written information, also provided in an audio format. The program covers goal setting, stress management through relaxation, breathing and mindfulness, pacing, physical activity, thoughts and emotions, sleep, nutrition, flare-up management, and planning.~The program was developed through a partnership between various chronic pain interest groups, and is hosted and managed by the Leadership Chair in Chronic Pain Education.-MEDISCA de l'Université Laval, Québec, Canada.~See ClinicalTrials entry NCT05319652 https://gerermadouleur.ca/agir-pour-moi/

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pain self-management program
Description: Agir pour moi (Acting for me) is a chronic pain self-management program designed to be followed independently online. The eight modules, normally spread over eight weeks and taking about 60 to 90 minutes per week to complete, focus on different strategies for managing pain on a daily basis.~The structured lessons include videos, audio capsules, activities, and written information, also provided in an audio format. The program covers goal setting, stress management through relaxation, breathing and mindfulness, pacing, physical activity, thoughts and emotions, sleep, nutrition, flare-up management, and planning.~The program was developed through a partnership between various chronic pain interest groups, and is hosted and managed by the Leadership Chair in Chronic Pain Education.-MEDISCA de l'Université Laval, Québec, Canada.~See ClinicalTrials entry NCT05319652 https://gerermadouleur.ca/agir-pour-moi/

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Additional support for self-management program
Description: This intervention is designed to give extra support to patients completing the online pain education program. It consists of two visits with a physiotherapist, and one group session led by a peer living with chronic musculoskeletal pain.~Sessions with the physiotherapist will occur at the beginning of the program and at the midway point. They will be used first to present the objectives and the components of the self-management program, to reinforce its potential to improve the participant's ability to manage their pain, and then to answer the participant's questions on the program and follow up on the regular completion of the lessons.~The group session will be co-facilitated by a physiotherapist and a patient-partner, and will include participants who have completed at least six weeks of the program. It will serve as a discussion forum to share helpful pain self-management strategies, lived experiences with pain and facilitators in completing the program.
Study: NCT06271408

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albuterol Sulfate, 2.5 Mg/3 mL (0.083%) Inhalation Solution
Description: Aerosolized albuterol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albuterol Sulfate, 2.5 Mg/3 mL (0.083%) Inhalation Solution
Description: Aerosolized albuterol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albuterol Sulfate, 2.5 Mg/3 mL (0.083%) Inhalation Solution
Description: Aerosolized albuterol

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vibrating Mesh Nebulizer
Description: A vibrating mesh nebulizer will be used to deliver aerosolized albuterol

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vibrating Mesh Nebulizer
Description: A vibrating mesh nebulizer will be used to deliver aerosolized albuterol

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vibrating Mesh Nebulizer
Description: A vibrating mesh nebulizer will be used to deliver aerosolized albuterol

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Metered Dose Inhaler
Description: A metered dose inhaler will be used to deliver aerosolized albuterol

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Metered Dose Inhaler
Description: A metered dose inhaler will be used to deliver aerosolized albuterol

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Metered Dose Inhaler
Description: A metered dose inhaler will be used to deliver aerosolized albuterol

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Jet Nebulizer
Description: A jet nebulizer will be used to deliver aerosolized albuterol

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Jet Nebulizer
Description: A jet nebulizer will be used to deliver aerosolized albuterol

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Jet Nebulizer
Description: A jet nebulizer will be used to deliver aerosolized albuterol
Study: NCT05361551

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Liver ablation
Description: Ablation needle placement An image-guidance device be used for planning of the procedure and for placement of the ablation needle
Study: NCT04717635

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Canakinumab
Description: Provide as 150 mg/1 mL solution for subcutaneous injection and administer 4mg/kg every 4 weeks.
Study: NCT05552027

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CCS System- Prototype
Description: Participants will be exposed to each of the 3 scenarios with the sensor system enabled (with feedback)

Intervention type: DEVICE
Group type: OTHER
Intervention: CCS System- Control
Description: The participants will be exposed to each of the 3 scenarios with the system disabled (no feedback).
Study: NCT05200208

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Citicoline supplement
Description: Participants with AD will receive a dietary citicoline supplement. Subjective sleep measures will be measured via the Pittsburgh Sleep Quality Index (for measurement of sleep quality) and Epworth Sleepiness Scale (for measurement of sleepiness). Cognition will be measured by Rey Auditory Verbal Learning Test (RAVLT), Trail Making Test (TMT) Parts A \& B, and the Montreal Cognitive Assessment (MOCA). Participants will complete all questionnaires at baseline and at follow-up at 3 months.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants with AD will receive a placebo supplement. Subjective sleep measures will be measured via the Pittsburgh Sleep Quality Index (for measurement of sleep quality) and Epworth Sleepiness Scale (for measurement of sleepiness). Cognition will be measured by Rey Auditory Verbal Learning Test (RAVLT), Trail Making Test (TMT) Parts A \& B, and the Montreal Cognitive Assessment (MOCA). Participants will complete all questionnaires at baseline and at follow-up at 3 months.
Study: NCT05788510

Intervention type: OTHER
Intervention: Pneumococcal vaccine
Description: Investigation of vaccination status, for Pneumococcal vaccine , of patients who received anti-TNF alpha therapy
Study: NCT05791981

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Harmony & Health Intervention
Description: Participants will attend group in person sessions 2 times each week for 8 weeks. The sessions will be 45 minutes long. In each session, there will be an introduction, 30 minutes of gentle yoga-based poses and breathing exercises, and then 10 minutes of guided relaxation and scripture meditation.~Participants will be instructed to practice the exercises at home 2 times each week during the entire 6-month period. You will be given instructions and a yoga mat, belt, and block. After your Week 9 assessment, you will attend in-person or Zoom sessions 1 time each month over the final 4 months of the study

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Attention Control
Description: Participants will attend group in-person health education sessions 2 times each week for 8 weeks. The sessions will be 45 minutes long and will include discussions of disease prevention and other health and well-being topics. After your Week 9 assessment, you will have the ability to attend additional in-person or Zoom health education sessions 1 time each month over the final 4 months of the study.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fitbit
Description: Participants will be given a Fitbit and instructions on how to use it. The Fitbit will record your physical activity and report it to the study staff.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fitbit
Description: Participants will be given a Fitbit and instructions on how to use it. The Fitbit will record your physical activity and report it to the study staff.
Study: NCT06572865

Intervention type: OTHER
Intervention: Screening for depression and anxiety
Description: Parents respond to questionnaires assessing depression and anxiety.
Study: NCT06459479

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conversational Artificial Intelligence Simulations
Description: Use of Conversational Artificial Intelligence Simulations generate medical scenario.
Study: NCT04696380

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine
Description: Participants will sample high vs low nicotine.
Study: NCT05410743

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 177Lu-LNC1010 1
Description: The patients were intravenously injected with single dose 2.22GBq (60 mCi) of 177Lu-LNC1010 and underwent 68Ga-DOTA-TATE PET/CT scans before and after the treatment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 177Lu-LNC1010 2
Description: The patients were intravenously injected with single dose 3.33GBq （90 mCi) of 177Lu-LNC1010 and underwent 68Ga-DOTA-TATE PET/CT scans before and after the treatment.
Study: NCT04696380

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine
Description: Participants will sample high vs low nicotine.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: JUUL e-cigarette
Description: Participants will sample preferred vs non-preferred JUUL flavors.
Study: NCT05410743

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 177Lu-LNC1010 3
Description: The patients were intravenously injected with single dose 4.99GBq (135 mCi) of 177Lu-LNC1010 and underwent 68Ga-DOTA-TATE PET/CT scans before and after the treatment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 177Lu-LNC1010 4
Description: Patients received a single, fixed dose of 177Lu-LNC1010 via intravenous injection, utilizing the well-tolerated and safe dose identified in Phase 1. They also underwent 68Ga-DOTA-TATE PET/CT scans both before and after the treatment to monitor their response.
Study: NCT04613362

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TENACITY Telehealth Cognitive Behavioral Therapy for Migraine
Description: Clinical health psychology therapy delivered via telehealth

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Behavioral Usual Care
Description: Behavioral usual care may include outpatient clinic-based health psychology in the VA or Community Care, or mindfulness sessions with LCSW.
Study: NCT04952779

Intervention type: DRUG
Intervention: Xultophy® (insulin degludec/liraglutide)
Description: Xultophy® is a fixed ratio combination of the long-acting basal insulin, insulin degludec, and the glucagon-like peptide 1 receptor agonist (GLP-1 RA), liraglutide, administered under the skin.~Patients will be treated according to routine clinical practice at the discretion of the treating physician according to the label approved by MFDS.~The assignment of the patient to Xultophy® is not decided in advance by the protocol but falls within current practice and the prescription of Xultophy® is clearly separated from the decision to include the patient in the study.
Study: NCT05725395

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual Reality
Description: During in-patient care participants will be randomized to receive or not receive the educational virtual reality intervention on the first day. After two days, participants will receive a total of 10 minutes interventional in the morning (between 8am to 12pm) every day until their in-patient care concludes.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual Reality
Description: During in-patient care participants will be randomized to receive or not receive the educational virtual reality intervention on the first day. After two days, participants will receive a total of 10 minutes interventional in the morning (between 8am to 12pm) every day until their in-patient care concludes.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard of Care
Description: For case control, participants will service as their self control and be randomized to receive no virtual reality intervention on either the first day or the second day of in-patient care.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard of Care
Description: For case control, participants will service as their self control and be randomized to receive no virtual reality intervention on either the first day or the second day of in-patient care.
Study: NCT06473233

Intervention type: DEVICE
Intervention: TEG6S
Description: Hemostatic management including one or more delocalized biology test with the TEG6S®, at the discretion of the responsible clinician
Study: NCT05427344

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Water exercise group
Description: Water exercise group where the Ai Chi technique was selected as the exercise method of choice. The activity will take place in a hydrotherapy pool approved by the Ministry of Health and will be led by a hydrotherapist who has been trained in Ai Chi.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Land exercise group
Description: Land exercise group who will perform the same Ai Chi movements on land in order to standardize the groups. The activity will take place in a hall and will be led by a physiotherapist who has been trained to teach Ai Chi on land.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control group
Description: Control group who will not perform additional physical activity or receive any extra treatments.